Trial Profile

A phase 1/2a study of SNK-01 for Parkinson's disease

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 02 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Troculeucel (Primary)
Indications Parkinson's disease
Focus Adverse reactions; Therapeutic Use

Most Recent Events

29 Apr 2024 According to NKGen Biotech media release, company announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for SNK01 NK cell therapy for the treatment of Parkinson's disease.
25 Apr 2024 According to NKGen Biotech media release, the company plan to initiate a Phase 1 trial in 2H 2024.
15 Apr 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com